SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around token burns tied to watcher milestones, fueling excitement and perceived scarcity. Talk centers on the strong community, the potential for significant upside, and a desire to reach number one on trending lists. The coin is built on the Solana network and the community is anticipating airdrop details.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Wayfinder

Wayfinder's PROMPT.X is trending with community members citing potential breakouts and significant gains, with some suggesting accumulation during dips. Bullish sentiment is fueled by mentions of strong support levels and potential short squeezes, while others point to increased volume and a possible reversal after a period of decline. The coin is being compared to other altcoins, with some speculating on potential future price targets.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending due to community speculation about a potential acquisition by Nvidia ($NVDA) and excitement surrounding its role in powering AI data centers. Traders are also closely monitoring insider trading activity and the impact of the new CEO on the company's strategic direction within the AI sector. Discussions also include potential breakout opportunities.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

Nobody Sausage is a unique online presence that embodies the playful, humorous side of internet culture. Created by Kael Cabral, this character has evolved into a beloved brand that resonates with people through its quirky personality and entertaining content.  Impact and Significance 1. Community building: Nobody Sausage has fostered a sense of community among its fans, who share and engage with its content, creating a collective experience. 2. Entertainment value: The character's quirky personality and humor provide endless entertainment for online audiences, making it a go-to destination for laughs and good times. 3. Cultural relevance: Nobody Sausage has become a symbol of the absurd, joyful aspects of internet culture, reflecting the ever-changing nature of online trends and memes.

Nobody Sausage

Nobody Sausage ($NOBODY.X) is trending as the community rallies behind it, aiming for substantial gains. Social media的热点似乎是其低市值和近期价格走势，投资者正密切关注其动量，一些人将其与之前的成功案例相比较。The focus is on potentially significant returns, similar to those seen with other recent coins.

bichi

BICHI.X is trending amid claims of substantial gains and community calls for coordinated buying to drive the price higher. Discussions highlight the token's low market cap and potential for significant returns, with some comparing it to other meme coins that have experienced rapid growth. The community is actively encouraging others to invest, referencing prior successes with similar tokens.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results 

CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

Company News for Sep 3, 2025

Companies In The News Are: SIG, PEP, CYTK, AL.

Retail chatter around Cytokinetics surged late&nbsp;Monday&nbsp;as the company’s shares jumped 34% in Europe after new data from its MAPLE-HCM study were presented at the European Society of Cardiology Congress 2025 in Madrid.Cytokinetics’ shares closed at €39.8 on Monday in Europe, up €10, or 33.6% from the prior session.The company stated that its experimental drug, aficamten, improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy, whereas treatment with the current standard of care, metoprolol, reduced it.The primary results were also published in The New England Journal of Medicine.MAPLE-HCM is a Phase 3 randomized, double-blind, active-comparator trial that enrolled 175 patients, who were assigned one-to-one to receive either aficamten or metoprolol as monotherapy.&nbsp;Cytokinetics said the trial was designed differently from its pivotal SEQUOIA-HCM study, enrolling patients with less severe disease, including those without obstruction at rest and with higher predicted peak oxygen uptake.Fady I. Malik, executive vice president of research and development, said the clinical difference between the two treatments was reinforced by secondary endpoints on symptoms, functional class and left ventricular outflow tract (LVOT) gradients, and that the benefits were seen in a broader patient population than in SEQUOIA-HCM.Cytokinetics also presented additional data from MAPLE-HCM at the ESC Congress, including a pre-specified analysis of aficamten’s effect on cardiac structure and function, published in the Journal of the American College of Cardiology.&nbsp;A late-breaking clinical science presentation on the incidence and impact of atrial fibrillation associated with aficamten was simultaneously published in Heart Rhythm.“The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy,” Malik said.&nbsp;On Stocktwits, retail sentiment for Cytokinetics was ‘extremely bullish’ amid a 150% surge in 24-hour message volume.One user stated that Cytokinetics appeared to be a clear buyout candidate, citing its head-to-head superiority over the standard-of-care metoprolol.<stembedurl>https://stocktwits.com/lebranjames/message/627145099</stembedurl>Another user noted that while Cytokinetics had strong data, it would still require significant funding, partnerships, and guideline updates before its drug could replace beta blockers, although they expected the stock to trade higher next week.&nbsp;<stembedurl>https://stocktwits.com/John62/message/627141611</stembedurl><a href="https://stocktwits.com/symbol/CYTK">Cytokinetics’ stock</a> has declined 25% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cytokinetics’ stock (CYTK) has declined 25% so far in 2025. (Photo credit: Getty Images)

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough 

The company unveiled Phase 3 MAPLE-HCM results showing aficamten outperformed metoprolol in obstructive hypertrophic cardiomyopathy, with findings published across top medical journals.

Equity

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Beats Q4 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK, Jan...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Current Price	$53.01
Prev Close	$49.75
Open	$50.71
Dividend Yield	0.00%
50-Day Moving Average	$37.20
Beta	0.91
Avg. Volume	1.69M
PE Ratio	-9.71

52-Week High	$59.39
52-Week Low	$29.31
Market Capitalization	$5.95B
EPS (Annual)	-$5.26
Price to Book	-16.14
Revenue Per Employee	$37,096.39
Enterprise Value/EBITDA	N/A

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTK Cytokinetics Inc